Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Charles Havnar, Daniel Oreper, Katrina Krogh, Richard Bourgon, Oliver A. Zill, Nicolas W. Lounsbury, Amy C. Y. Lo, Thomas D. Wu, Ryan Jones, Ximo Pechuan-Jorge, Guang Yu Yang, Andrew J Wallace
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundIndividualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges. It is
Autor:
Sharon Ng, Meenal Sinha, Rahul Aggarwal, Terence W. Friedlander, Christopher Nguyen, Li Zhang, Sumit K. Subudhi, Brandon Chen, E Liu, Alexander Cheung, Padmanee Sharma, Kate Allaire, James P. Allison, Lawrence Fong, Matthew H. Spitzer, Eric J. Small, Jaqueline Marquez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
BackgroundSipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after
Autor:
Li Huo, Jianzhen Lin, Jie Pan, Xu Yang, Xiaobo Yang, Junyu Long, Ying Hu, Jinzhu Mao, Jiao Zhang, Jin Bian, Xinting Sang, Henghui Zhang, Xi Wang, Ke Hu, Keyan Yang, Haitao Zhao, Mei Guan, Fucun Xie, Dongxu Wang, Yilei Mao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThis study was designed to screen potential biomarkers in plasma cell-free DNA (cfDNA) for predicting the clinical outcome of immune checkpoint inhibitor (ICI)-based therapy in advanced hepatobiliary cancers.MethodsThree cohorts including 1
Autor:
Myrto Moutafi, James Haberberger, Brian M. Alexander, Wei Wei, Weiwei Tao, David L. Rimm, Konstantinos N. Syrigos, Richard S.P. Huang, Ioannis A. Vathiotis, Jeffrey S. Ross, Lajos Pusztai, Shakti H. Ramkissoon
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Assessment of programmed cell death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is the definite diagnostic test to guide treatment for patients with advanced-stage non-small cell lung cancer. Intratumoral heterogeneity and discrepancy o
Autor:
Joao Victor Machado Alessi, Biagio Ricciuti, Greg Jones, Gonzalo Recondo, Mizuki Nishino, Tim Forshew, Michael Cheng, Mariano Severgnini, Marissa N. Lawrence, Christine A. Lydon, Mark M. Awad
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundCurrently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for patients with advanced non-small cell lung cancer (NSCLC). Having an early pharmacodynamic marker
Autor:
Yunpeng Yang, Yang Zhang, Hua Bao, Xue Wu, Wanxiangfu Tang, Shaodong Hong, Wenfeng Fang, Ao Wang, Yang Shao, Li Zhang, Yan Huang, Qingguang Lin, Yuxiang Ma, Hongyun Zhao, Xi Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAnti-programmed death (PD)-1 therapy has recently been used in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). The long-term survival and its biomarkers responding to anti-PD-1 treatment in patients with R/M NPC remain unclear
Autor:
Ala Abudayyeh, Cassian Yee, Nizar M. Tannir, Maria E. Suarez-Almazor, Shana Machado, Biruh Workeneh, Sheldon Chen, Amanda Tchakarov, Umut Selamet, Lillian W. Gaber, Huifang Lu, William F Glass, Amit Lahoti, Omar Mamlouk, Jamie S. Lin, Noha Abdel-Wahab, Maen Abdelrahim, Jean Tayar, Adi Diab
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Rationale & Objective The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these age
Autor:
Yukio Kageyama, Minato Yokoyama, Soichiro Yoshida, Kazutaka Saito, Junichiro Ishioka, Yoh Matsuoka, Shohei Fukuda, Yasuhisa Fujii, Yosuke Yasuda, Toshiki Kijima
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundThe dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor era. We investigated the impact of early CRP kinetics on the efficacy of
Autor:
Daan P. Hurkmans, Stijn L.W. Koolen, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Morten A. Karsdal, Nicholas Willumsen, Christina Jensen
Publikováno v:
Journal for ImmunoTherapy of Cancer, 8(2):e001193. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundImmune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor induce a response in only a subgroup of patients with metastatic melanoma. Previous research suggests that transforming growth factor beta signalin
Autor:
Vit Drochytek, Ladislav Pecen, Ludek Sojka, Sarka Vosahlikova, Tomas Brtnicky, Michal Hensler, Tereza Lanickova, Jelena Pistolic, Jan Laco, Lorenzo Galluzzi, Vladimir Benes, Jana Rakova, Iva Truxova, Lenka Kasikova, Radek Spisek, Wolf Hervé Fridman, Ales Ryska, Ivan Praznovec, Jitka Fucikova, Irena Moserova, Karel Fiser, Petr Skapa, Catherine Sautès-Fridman, Martina Rehackova, Lukas Rob
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (2), pp.e000979. ⟨10.1136/jitc-2020-000979⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (2), pp.e000979. ⟨10.1136/jitc-2020-000979⟩
BackgroundThe immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient surviva